Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 135 participants.
Also called NCT05140694
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 135 participants
- Registry
-
NCT05140694
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT05140694. Randomized; double masking; primary purpose treatment. Start 2023-12-01 (anticipated); primary completion 2024-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
- Condition
- Metabolic-associated Fatty Liver Disease
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Dulaglutide
- Intervention (Drug)
- Empagliflozin and Dulaglutide
- Lead sponsor
- Seoul National University Bundang Hospital
Record details
- Record id
cardio:ct-nct05140694- Content hash
32c9d82832e2fe03d9658c5419a922efe920faea3600e67bfe5d1a59239ab8e1